<DOC>
	<DOCNO>NCT00324415</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin fluorouracil , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiation therapy use high-energy x-ray kill tumor cell . Giving cisplatin , fluorouracil , cetuximab together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give cisplatin , fluorouracil , cetuximab together radiation therapy work treat patient HIV stage I , stage II , stage III anal cancer .</brief_summary>
	<brief_title>Combined Modality Therapy Patients With With HIV Stage I , Stage II , Stage III Anal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year local failure rate patient HIV-associated stage I-IIIB anal carcinoma treat cisplatin , fluorouracil , cetuximab , radiotherapy . - Determine objective response rate ( complete partial ) , progression-free survival , relapse-free survival , colostomy-free survival , overall survival , quality life , overall toxicity patient treated regimen . Secondary - Characterize effect regimen underlie HIV condition describe change viral load , CD4 count , incidence opportunistic illness , include development AIDS first year treatment . - Evaluate effect regimen anogenital human papilloma virus ( HPV ) infection anal cytology . OUTLINE : This open-label , multicenter study . Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 35* , fluorouracil IV continuously day 1-4 29-32 , cisplatin IV 1 hour day 1 29 . Beginning day 1 , patient undergo concurrent radiotherapy primary tumor 5 day week 5-7 week . Treatment continue absence disease progression unacceptable toxicity . NOTE : *Patients receive 7 week radiotherapy also receive cetuximab day 42 49 . Quality life assess baseline , completion study treatment , month 3 , 6 , 12 , 24 , 36 . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 47 patient accrue study .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIIIB invasive anal canal perianal ( anal margin ) squamous cell carcinoma , include tumor follow nonkeratinizing histology : Basaloid Transitional cell Cloacogenic Documented HIV infection 1 following : Antibody detection Culture Quantitative assay plasma HIV RNA PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL ( transfusion , epoetin alfa , myeloid growth factor support allow provide blood count stable ≥ 2 week prior study entry ) Creatinine ≤ 1.5 time upper limit normal ( ULN ) OR creatinine clearance &gt; 60 mL/min AST ALT ≤ 3 time ULN Bilirubin ≤ 2 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No acute active , serious , uncontrolled opportunistic infection No prior invasive malignancy diagnose within past 24 month , exclude situ cervical cancer , anal dysplasia carcinoma situ , nonmelanoma skin carcinoma , Kaposi 's sarcoma require systemic chemotherapy within past 24 month No peripheral neuropathy &gt; grade 1 No severe poorly control diarrhea No medical psychiatric illness would preclude study requirement PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy malignancy Prior radiotherapy another condition ( e.g. , Kaposi 's sarcoma ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage I anal cancer</keyword>
	<keyword>stage II anal cancer</keyword>
	<keyword>stage IIIA anal cancer</keyword>
	<keyword>stage IIIB anal cancer</keyword>
	<keyword>squamous cell carcinoma anus</keyword>
	<keyword>basaloid carcinoma anus</keyword>
	<keyword>cloacogenic carcinoma anus</keyword>
</DOC>